New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices - Episode 4

Tafasitamab and Lenalidomide for R/R DLBCL

, , , , ,

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

EP. 1: Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma
EP. 2: Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL
EP. 3: Treatment Selection in Second Line R/R DLBCL
Now Viewing
EP. 4: Tafasitamab and Lenalidomide for R/R DLBCL
EP. 5: Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL
EP. 6: The Role of CAR T-Cell Therapy in R/R DLBCL
EP. 7: Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL
EP. 8: Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma
EP. 9: Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL
EP. 10: Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting
EP. 11: Bispecifics for Third Line Therapy of R/R DLBCL
EP. 12: R/R DLBCL: Safety Considerations for Bispecific Antibodies
EP. 13: Treatment Sequencing of Later Line Therapies in R/R DLBCL
EP. 14: Additional Data Updates from ASH 2023
EP. 15: Future Outlooks in the Treatment of R/R DLBCL

Related Content:

New Treatment Options for DLBCL: Impact on Sequencing Therapeutic ChoicesOncLive Peer Exchange® Hematologic Oncology
An Era of Firsts in CML: Asciminib Challenges SOC TKIs
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management
Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice